Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation

The use of immune checkpoint inhibitors (ICI) in cancer patients with solid organ allografts is hampered due to potential organ rejection. Here, the authors present a case report of a patient with kidney allograft and show that treatment with the mTOR inhibitor sirolimus preserves peripheral toleran...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Khashayar Esfahani, Tho-Alfakar Al-Aubodah, Pamela Thebault, Réjean Lapointe, Marie Hudson, Nathalie A. Johnson, Dana Baran, Najwa Bhulaiga, Tomoko Takano, Jean-François Cailhier, Ciriaco A. Piccirillo, Wilson H. Miller
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2019
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/7b6d74e8eca445f991f3a9a988480cef
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7b6d74e8eca445f991f3a9a988480cef
record_format	dspace
spelling	oai:doaj.org-article:7b6d74e8eca445f991f3a9a988480cef2021-12-02T14:39:39ZTargeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation10.1038/s41467-019-12628-12041-1723https://doaj.org/article/7b6d74e8eca445f991f3a9a988480cef2019-10-01T00:00:00Zhttps://doi.org/10.1038/s41467-019-12628-1https://doaj.org/toc/2041-1723The use of immune checkpoint inhibitors (ICI) in cancer patients with solid organ allografts is hampered due to potential organ rejection. Here, the authors present a case report of a patient with kidney allograft and show that treatment with the mTOR inhibitor sirolimus preserves peripheral tolerance and anti-tumour efficacy of ICI therapy.Khashayar EsfahaniTho-Alfakar Al-AubodahPamela ThebaultRéjean LapointeMarie HudsonNathalie A. JohnsonDana BaranNajwa BhulaigaTomoko TakanoJean-François CailhierCiriaco A. PiccirilloWilson H. MillerNature PortfolioarticleScienceQENNature Communications, Vol 10, Iss 1, Pp 1-9 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Khashayar Esfahani Tho-Alfakar Al-Aubodah Pamela Thebault Réjean Lapointe Marie Hudson Nathalie A. Johnson Dana Baran Najwa Bhulaiga Tomoko Takano Jean-François Cailhier Ciriaco A. Piccirillo Wilson H. Miller Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
description	The use of immune checkpoint inhibitors (ICI) in cancer patients with solid organ allografts is hampered due to potential organ rejection. Here, the authors present a case report of a patient with kidney allograft and show that treatment with the mTOR inhibitor sirolimus preserves peripheral tolerance and anti-tumour efficacy of ICI therapy.
format	article
author	Khashayar Esfahani Tho-Alfakar Al-Aubodah Pamela Thebault Réjean Lapointe Marie Hudson Nathalie A. Johnson Dana Baran Najwa Bhulaiga Tomoko Takano Jean-François Cailhier Ciriaco A. Piccirillo Wilson H. Miller
author_facet	Khashayar Esfahani Tho-Alfakar Al-Aubodah Pamela Thebault Réjean Lapointe Marie Hudson Nathalie A. Johnson Dana Baran Najwa Bhulaiga Tomoko Takano Jean-François Cailhier Ciriaco A. Piccirillo Wilson H. Miller
author_sort	Khashayar Esfahani
title	Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
title_short	Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
title_full	Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
title_fullStr	Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
title_full_unstemmed	Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation
title_sort	targeting the mtor pathway uncouples the efficacy and toxicity of pd-1 blockade in renal transplantation
publisher	Nature Portfolio
publishDate	2019
url	https://doaj.org/article/7b6d74e8eca445f991f3a9a988480cef
work_keys_str_mv	AT khashayaresfahani targetingthemtorpathwayuncouplestheefficacyandtoxicityofpd1blockadeinrenaltransplantation AT thoalfakaralaubodah targetingthemtorpathwayuncouplestheefficacyandtoxicityofpd1blockadeinrenaltransplantation AT pamelathebault targetingthemtorpathwayuncouplestheefficacyandtoxicityofpd1blockadeinrenaltransplantation AT rejeanlapointe targetingthemtorpathwayuncouplestheefficacyandtoxicityofpd1blockadeinrenaltransplantation AT mariehudson targetingthemtorpathwayuncouplestheefficacyandtoxicityofpd1blockadeinrenaltransplantation AT nathalieajohnson targetingthemtorpathwayuncouplestheefficacyandtoxicityofpd1blockadeinrenaltransplantation AT danabaran targetingthemtorpathwayuncouplestheefficacyandtoxicityofpd1blockadeinrenaltransplantation AT najwabhulaiga targetingthemtorpathwayuncouplestheefficacyandtoxicityofpd1blockadeinrenaltransplantation AT tomokotakano targetingthemtorpathwayuncouplestheefficacyandtoxicityofpd1blockadeinrenaltransplantation AT jeanfrancoiscailhier targetingthemtorpathwayuncouplestheefficacyandtoxicityofpd1blockadeinrenaltransplantation AT ciriacoapiccirillo targetingthemtorpathwayuncouplestheefficacyandtoxicityofpd1blockadeinrenaltransplantation AT wilsonhmiller targetingthemtorpathwayuncouplestheefficacyandtoxicityofpd1blockadeinrenaltransplantation
_version_	1718390540410552320

Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation

Ejemplares similares